Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q16651
UPID:
PRSS8_HUMAN
Alternative names:
Channel-activating protease 1; Serine protease 8
Alternative UPACC:
Q16651; B4DWP2; Q9UCA3
Background:
Prostasin, also known as Channel-activating protease 1 or Serine protease 8, is a protein with a unique trypsin-like cleavage specificity, favoring poly-basic substrates. It plays a crucial role in stimulating the epithelial sodium channel (ENaC) activity by activating cleavage of the gamma subunits (SCNN1G).
Therapeutic significance:
Understanding the role of Prostasin could open doors to potential therapeutic strategies.